Biodesix, Inc. reaffirmed revenue guidance for the year 2022. For the year, company expects to generate between $37.5 million and $39.5 million in total revenue in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.58 USD | -4.24% |
|
-1.86% | -14.13% |
21/05 | Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting | CI |
13/05 | TD Cowen Starts Biodesix With Buy Rating, $2.80 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.13% | 23Cr | |
-18.45% | 852.76Cr | |
+65.89% | 426.14Cr | |
+6.21% | 271.18Cr | |
-1.93% | 263.46Cr | |
-57.14% | 171.66Cr | |
-19.16% | 167.05Cr | |
-20.01% | 144.66Cr | |
+15.38% | 118.85Cr | |
-50.40% | 101.08Cr |
- Stock Market
- Equities
- BDSX Stock
- News Biodesix, Inc.
- Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022